ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Infliximab for Injection Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-3I20174
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Infliximab for Injection Market Outlook In Depth Analysis Forecast to 2031
BUY CHAPTERS

Global Infliximab for Injection Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-3I20174
Report
November 2025
Pages:120
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Kexing Biopharm
Xian Janssen Pharmaceutical
Mabpharm
Janssen

Infliximab for Injection Market

The global Infliximab for Injection market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
From a downstream perspective, Rheumatoid Arthritis accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Infliximab for Injection leading manufacturers including Kexing Biopharm, Xian Janssen Pharmaceutical, Mabpharm, Janssen, etc., dominate supply; the top five capture approximately % of global revenue, with Kexing Biopharm leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Infliximab for Injection market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Infliximab for Injection Market Report

Report Metric Details
Report Name Infliximab for Injection Market
Segment by Type
  • White Solid
  • Others
Segment by Application
  • Rheumatoid Arthritis
  • Fistula Crohn's Disease
  • Ankylosing Spondylitis
  • Psoriasis
  • Ulcerative Colitis in Adults
  • Others
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Kexing Biopharm, Xian Janssen Pharmaceutical, Mabpharm, Janssen
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Infliximab for Injection study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Infliximab for Injection Market report?

Ans: The main players in the Infliximab for Injection Market are Kexing Biopharm, Xian Janssen Pharmaceutical, Mabpharm, Janssen

What are the Application segmentation covered in the Infliximab for Injection Market report?

Ans: The Applications covered in the Infliximab for Injection Market report are Rheumatoid Arthritis, Fistula Crohn's Disease, Ankylosing Spondylitis, Psoriasis, Ulcerative Colitis in Adults, Others

What are the Type segmentation covered in the Infliximab for Injection Market report?

Ans: The Types covered in the Infliximab for Injection Market report are White Solid, Others

1 Study Coverage
1.1 Introduction to Infliximab for Injection: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Infliximab for Injection Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 White Solid
1.2.3 Others
1.3 Market Segmentation by Application
1.3.1 Global Infliximab for Injection Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Rheumatoid Arthritis
1.3.3 Fistula Crohn's Disease
1.3.4 Ankylosing Spondylitis
1.3.5 Psoriasis
1.3.6 Ulcerative Colitis in Adults
1.3.7 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Infliximab for Injection Revenue Estimates and Forecasts 2020-2031
2.2 Global Infliximab for Injection Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Infliximab for Injection Sales Estimates and Forecasts 2020-2031
2.4 Global Infliximab for Injection Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Infliximab for Injection Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Infliximab for Injection Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 White Solid Market Size by Manufacturers
3.5.2 Others Market Size by Manufacturers
3.6 Global Infliximab for Injection Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Infliximab for Injection Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Infliximab for Injection Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Infliximab for Injection Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Infliximab for Injection Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Infliximab for Injection Sales and Revenue by Type (2020-2031)
6.4 North America Infliximab for Injection Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Infliximab for Injection Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Infliximab for Injection Sales and Revenue by Type (2020-2031)
7.4 Europe Infliximab for Injection Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Infliximab for Injection Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Infliximab for Injection Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Infliximab for Injection Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Infliximab for Injection Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Infliximab for Injection Sales and Revenue by Type (2020-2031)
9.4 Central and South America Infliximab for Injection Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Infliximab for Injection Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Infliximab for Injection Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Infliximab for Injection Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Infliximab for Injection Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Kexing Biopharm
11.1.1 Kexing Biopharm Corporation Information
11.1.2 Kexing Biopharm Business Overview
11.1.3 Kexing Biopharm Infliximab for Injection Product Models, Descriptions and Specifications
11.1.4 Kexing Biopharm Infliximab for Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Kexing Biopharm Infliximab for Injection Sales by Product in 2024
11.1.6 Kexing Biopharm Infliximab for Injection Sales by Application in 2024
11.1.7 Kexing Biopharm Infliximab for Injection Sales by Geographic Area in 2024
11.1.8 Kexing Biopharm Infliximab for Injection SWOT Analysis
11.1.9 Kexing Biopharm Recent Developments
11.2 Xian Janssen Pharmaceutical
11.2.1 Xian Janssen Pharmaceutical Corporation Information
11.2.2 Xian Janssen Pharmaceutical Business Overview
11.2.3 Xian Janssen Pharmaceutical Infliximab for Injection Product Models, Descriptions and Specifications
11.2.4 Xian Janssen Pharmaceutical Infliximab for Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Xian Janssen Pharmaceutical Infliximab for Injection Sales by Product in 2024
11.2.6 Xian Janssen Pharmaceutical Infliximab for Injection Sales by Application in 2024
11.2.7 Xian Janssen Pharmaceutical Infliximab for Injection Sales by Geographic Area in 2024
11.2.8 Xian Janssen Pharmaceutical Infliximab for Injection SWOT Analysis
11.2.9 Xian Janssen Pharmaceutical Recent Developments
11.3 Mabpharm
11.3.1 Mabpharm Corporation Information
11.3.2 Mabpharm Business Overview
11.3.3 Mabpharm Infliximab for Injection Product Models, Descriptions and Specifications
11.3.4 Mabpharm Infliximab for Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Mabpharm Infliximab for Injection Sales by Product in 2024
11.3.6 Mabpharm Infliximab for Injection Sales by Application in 2024
11.3.7 Mabpharm Infliximab for Injection Sales by Geographic Area in 2024
11.3.8 Mabpharm Infliximab for Injection SWOT Analysis
11.3.9 Mabpharm Recent Developments
11.4 Janssen
11.4.1 Janssen Corporation Information
11.4.2 Janssen Business Overview
11.4.3 Janssen Infliximab for Injection Product Models, Descriptions and Specifications
11.4.4 Janssen Infliximab for Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Janssen Infliximab for Injection Sales by Product in 2024
11.4.6 Janssen Infliximab for Injection Sales by Application in 2024
11.4.7 Janssen Infliximab for Injection Sales by Geographic Area in 2024
11.4.8 Janssen Infliximab for Injection SWOT Analysis
11.4.9 Janssen Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Infliximab for Injection Industry Chain
12.2 Infliximab for Injection Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Infliximab for Injection Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Infliximab for Injection Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Infliximab for Injection Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Infliximab for Injection Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Kexing Biopharm
Xian Janssen Pharmaceutical
Mabpharm
Janssen
List of Tables
 Table 1. Global Infliximab for Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Infliximab for Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Infliximab for Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Infliximab for Injection Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Infliximab for Injection Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Infliximab for Injection Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Dose)
 Table 7. Global Infliximab for Injection Sales by Region (2020-2025) & (K Dose)
 Table 8. Global Infliximab for Injection Sales by Region (2026-2031) & (K Dose)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Infliximab for Injection Sales by Manufacturers (2020-2025) & (K Dose)
 Table 11. Global Infliximab for Injection Sales Share by Manufacturers (2020-2025)
 Table 12. Global Infliximab for Injection Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Infliximab for Injection Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Infliximab for Injection by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Infliximab for Injection as of 2024)
 Table 16. Global Infliximab for Injection Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Infliximab for Injection Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Dose)
 Table 18. Key Manufacturers Infliximab for Injection Manufacturing Base and Headquarters
 Table 19. Global Infliximab for Injection Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Infliximab for Injection Sales by Type (2020-2025) & (K Dose)
 Table 23. Global Infliximab for Injection Sales by Type (2026-2031) & (K Dose)
 Table 24. Global Infliximab for Injection Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Infliximab for Injection Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Infliximab for Injection ASP by Type (2020-2031) & (US$/Dose)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Infliximab for Injection Sales by Application (2020-2025) & (K Dose)
 Table 29. Global Infliximab for Injection Sales by Application (2026-2031) & (K Dose)
 Table 30. Infliximab for Injection High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Infliximab for Injection Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Infliximab for Injection Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Infliximab for Injection ASP by Application (2020-2031) & (US$/Dose)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Infliximab for Injection Growth Accelerators and Market Barriers
 Table 37. North America Infliximab for Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Infliximab for Injection Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Infliximab for Injection Growth Accelerators and Market Barriers
 Table 40. Europe Infliximab for Injection Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Infliximab for Injection Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Infliximab for Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Infliximab for Injection Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Infliximab for Injection Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Infliximab for Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Infliximab for Injection Investment Opportunities and Key Challenges
 Table 47. Central and South America Infliximab for Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Infliximab for Injection Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Infliximab for Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Kexing Biopharm Corporation Information
 Table 51. Kexing Biopharm Description and Major Businesses
 Table 52. Kexing Biopharm Product Models, Descriptions and Specifications
 Table 53. Kexing Biopharm Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 54. Kexing Biopharm Sales Value Proportion by Product in 2024
 Table 55. Kexing Biopharm Sales Value Proportion by Application in 2024
 Table 56. Kexing Biopharm Sales Value Proportion by Geographic Area in 2024
 Table 57. Kexing Biopharm Infliximab for Injection SWOT Analysis
 Table 58. Kexing Biopharm Recent Developments
 Table 59. Xian Janssen Pharmaceutical Corporation Information
 Table 60. Xian Janssen Pharmaceutical Description and Major Businesses
 Table 61. Xian Janssen Pharmaceutical Product Models, Descriptions and Specifications
 Table 62. Xian Janssen Pharmaceutical Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 63. Xian Janssen Pharmaceutical Sales Value Proportion by Product in 2024
 Table 64. Xian Janssen Pharmaceutical Sales Value Proportion by Application in 2024
 Table 65. Xian Janssen Pharmaceutical Sales Value Proportion by Geographic Area in 2024
 Table 66. Xian Janssen Pharmaceutical Infliximab for Injection SWOT Analysis
 Table 67. Xian Janssen Pharmaceutical Recent Developments
 Table 68. Mabpharm Corporation Information
 Table 69. Mabpharm Description and Major Businesses
 Table 70. Mabpharm Product Models, Descriptions and Specifications
 Table 71. Mabpharm Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 72. Mabpharm Sales Value Proportion by Product in 2024
 Table 73. Mabpharm Sales Value Proportion by Application in 2024
 Table 74. Mabpharm Sales Value Proportion by Geographic Area in 2024
 Table 75. Mabpharm Infliximab for Injection SWOT Analysis
 Table 76. Mabpharm Recent Developments
 Table 77. Janssen Corporation Information
 Table 78. Janssen Description and Major Businesses
 Table 79. Janssen Product Models, Descriptions and Specifications
 Table 80. Janssen Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 81. Janssen Sales Value Proportion by Product in 2024
 Table 82. Janssen Sales Value Proportion by Application in 2024
 Table 83. Janssen Sales Value Proportion by Geographic Area in 2024
 Table 84. Janssen Infliximab for Injection SWOT Analysis
 Table 85. Janssen Recent Developments
 Table 86. Key Raw Materials Distribution
 Table 87. Raw Materials Key Suppliers
 Table 88. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 89. Milestones in Production Technology Evolution
 Table 90. Distributors List
 Table 91. Market Trends and Market Evolution
 Table 92. Market Drivers and Opportunities
 Table 93. Market Challenges, Risks, and Restraints
 Table 94. Research Programs/Design for This Report
 Table 95. Key Data Information from Secondary Sources
 Table 96. Key Data Information from Primary Sources


List of Figures
 Figure 1. Infliximab for Injection Product Picture
 Figure 2. Global Infliximab for Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. White Solid Product Picture
 Figure 4. Others Product Picture
 Figure 5. Global Infliximab for Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Rheumatoid Arthritis
 Figure 7. Fistula Crohn's Disease
 Figure 8. Ankylosing Spondylitis
 Figure 9. Psoriasis
 Figure 10. Ulcerative Colitis in Adults
 Figure 11. Others
 Figure 12. Infliximab for Injection Report Years Considered
 Figure 13. Global Infliximab for Injection Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Infliximab for Injection Revenue (2020-2031) & (US$ Million)
 Figure 15. Global Infliximab for Injection Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 16. Global Infliximab for Injection Revenue Market Share by Region (2020-2031)
 Figure 17. Global Infliximab for Injection Sales (2020-2031) & (K Dose)
 Figure 18. Global Infliximab for Injection Sales (CAGR) by Region (2020-2031) (K Dose)
 Figure 19. Global Infliximab for Injection Sales Market Share by Region (2020-2031)
 Figure 20. Top 5 and Top 10 Manufacturers Infliximab for Injection Sales Volume Market Share in 2024
 Figure 21. Global Infliximab for Injection Revenue Market Share Ranking (2024)
 Figure 22. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 23. White Solid Revenue Market Share by Manufacturer in 2024
 Figure 24. Others Revenue Market Share by Manufacturer in 2024
 Figure 25. Global Infliximab for Injection Sales Market Share by Type (2020-2031)
 Figure 26. Global Infliximab for Injection Revenue Market Share by Type (2020-2031)
 Figure 27. Global Infliximab for Injection Sales Market Share by Application (2020-2031)
 Figure 28. Global Infliximab for Injection Revenue Market Share by Application (2020-2031)
 Figure 29. North America Infliximab for Injection Sales YoY (2020-2031) & (K Dose)
 Figure 30. North America Infliximab for Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 31. North America Top 5 Manufacturers Infliximab for Injection Sales Revenue (US$ Million) in 2024
 Figure 32. North America Infliximab for Injection Sales Volume (K Dose) by Type (2020- 2031)
 Figure 33. North America Infliximab for Injection Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 34. North America Infliximab for Injection Sales Volume (K Dose) by Application (2020-2031)
 Figure 35. North America Infliximab for Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 36. US Infliximab for Injection Revenue (2020-2031) & (US$ Million)
 Figure 37. Canada Infliximab for Injection Revenue (2020-2031) & (US$ Million)
 Figure 38. Mexico Infliximab for Injection Revenue (2020-2031) & (US$ Million)
 Figure 39. Europe Infliximab for Injection Sales YoY (2020-2031) & (K Dose)
 Figure 40. Europe Infliximab for Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 41. Europe Top 5 Manufacturers Infliximab for Injection Sales Revenue (US$ Million) in 2024
 Figure 42. Europe Infliximab for Injection Sales Volume (K Dose) by Type (2020-2031)
 Figure 43. Europe Infliximab for Injection Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 44. Europe Infliximab for Injection Sales Volume (K Dose) by Application (2020-2031)
 Figure 45. Europe Infliximab for Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 46. Germany Infliximab for Injection Revenue (2020-2031) & (US$ Million)
 Figure 47. France Infliximab for Injection Revenue (2020-2031) & (US$ Million)
 Figure 48. U.K. Infliximab for Injection Revenue (2020-2031) & (US$ Million)
 Figure 49. Italy Infliximab for Injection Revenue (2020-2031) & (US$ Million)
 Figure 50. Russia Infliximab for Injection Revenue (2020-2031) & (US$ Million)
 Figure 51. Asia-Pacific Infliximab for Injection Sales YoY (2020-2031) & (K Dose)
 Figure 52. Asia-Pacific Infliximab for Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 53. Asia-Pacific Top 8 Manufacturers Infliximab for Injection Sales Revenue (US$ Million) in 2024
 Figure 54. Asia-Pacific Infliximab for Injection Sales Volume (K Dose) by Type (2020- 2031)
 Figure 55. Asia-Pacific Infliximab for Injection Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 56. Asia-Pacific Infliximab for Injection Sales Volume (K Dose) by Application (2020-2031)
 Figure 57. Asia-Pacific Infliximab for Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 58. Indonesia Infliximab for Injection Revenue (2020-2031) & (US$ Million)
 Figure 59. Japan Infliximab for Injection Revenue (2020-2031) & (US$ Million)
 Figure 60. South Korea Infliximab for Injection Revenue (2020-2031) & (US$ Million)
 Figure 61. China Taiwan Infliximab for Injection Revenue (2020-2031) & (US$ Million)
 Figure 62. India Infliximab for Injection Revenue (2020-2031) & (US$ Million)
 Figure 63. Central and South America Infliximab for Injection Sales YoY (2020-2031) & (K Dose)
 Figure 64. Central and South America Infliximab for Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 65. Central and South America Top 5 Manufacturers Infliximab for Injection Sales Revenue (US$ Million) in 2024
 Figure 66. Central and South America Infliximab for Injection Sales Volume (K Dose) by Type (2021-2031)
 Figure 67. Central and South America Infliximab for Injection Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 68. Central and South America Infliximab for Injection Sales Volume (K Dose) by Application (2020-2031)
 Figure 69. Central and South America Infliximab for Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 70. Brazil Infliximab for Injection Revenue (2020-2025) & (US$ Million)
 Figure 71. Argentina Infliximab for Injection Revenue (2020-2025) & (US$ Million)
 Figure 72. Middle East, and Africa Infliximab for Injection Sales YoY (2020-2031) & (K Dose)
 Figure 73. Middle East and Africa Infliximab for Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 74. Middle East and Africa Top 5 Manufacturers Infliximab for Injection Sales Revenue (US$ Million) in 2024
 Figure 75. Middle East and Africa Infliximab for Injection Sales Volume (K Dose) by Type (2021-2031)
 Figure 76. South America Infliximab for Injection Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 77. Middle East and Africa Infliximab for Injection Sales Volume (K Dose) by Application (2020-2031)
 Figure 78. Middle East and Africa Infliximab for Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 79. GCC Countries Infliximab for Injection Revenue (2020-2025) & (US$ Million)
 Figure 80. Turkey Infliximab for Injection Revenue (2020-2025) & (US$ Million)
 Figure 81. Egypt Infliximab for Injection Revenue (2020-2025) & (US$ Million)
 Figure 82. South Africa Infliximab for Injection Revenue (2020-2025) & (US$ Million)
 Figure 83. Infliximab for Injection Industry Chain Mapping
 Figure 84. Regional Infliximab for Injection Manufacturing Base Distribution (%)
 Figure 85. Global Infliximab for Injection Production Market Share by Region (2020-2031)
 Figure 86. Infliximab for Injection Production Process
 Figure 87. Regional Infliximab for Injection Production Cost Structure
 Figure 88. Channels of Distribution (Direct Vs Distribution)
 Figure 89. Bottom-up and Top-down Approaches for This Report
 Figure 90. Data Triangulation
 Figure 91. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Direct Compressible Excipients Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10S20265
Wed Nov 19 00:00:00 UTC 2025

Add to Cart

Global Bacteria Collection Incubator Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-7N20275
Wed Nov 19 00:00:00 UTC 2025

Add to Cart

Global Microbial Biopreservatives Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14I20188
Mon Nov 17 00:00:00 UTC 2025

Add to Cart

Global Perfluoroheptanoic Acid Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3O20200
Mon Nov 17 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions